Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab

Background: Adalimumab, a human anti-tumor necrosis factor-ɑ monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis. This is the first case series of adalimumab administrations for relentless placoid chorioretinitis (RPC) patients. Case...

Full description

Bibliographic Details

Published in:	Case Reports in Ophthalmology
Main Authors:	Shotaro Asano, Rie Tanaka, Hidetoshi Kawashima, Toshikatsu Kaburaki
Format:	Article
Language:	English
Published:	Karger Publishers 2019-05-01
Subjects:	Relentless placoid chorioretinitis Adalimumab Uveitis Acute posterior multifocal placoid pigment epitheliopathy Serpiginous choroiditis
Online Access:	https://www.karger.com/Article/FullText/500077